下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEOrteronelCat.No.:HY-10505CASNo.:566939-85-3Synonyms:TAK-700分?式:C??H??N?O?分?量:307.35作?靶點(diǎn):CytochromeP450作?通路:MetabolicEnzyme/Protease儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:14.29mg/mL(46.49mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.2536mL16.2681mL32.5362mL5mM0.6507mL3.2536mL6.5072mL10mM0.3254mL1.6268mL3.2536mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;?旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥1.43mg/mL(4.65mM);Clearsolution2.請(qǐng)依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥1.43mg/mL(4.65mM);Clearsolution3.請(qǐng)依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥1.43mg/mL(4.65mM);ClearsolutionBIOLOGICALACTIVITY?物活性O(shè)rteronel(TAK-700)?種?度選擇性的?17,20-裂解酶(17,20-lyase,CYP17)抑制劑,IC50值為38nM,對(duì)其選擇性對(duì)11-hydroxylase和CYP3A4的1000多倍[1][2]。IC50&TargetIC50:38nM(human17,20-lyase),54nM(rat17,20-lyase)體外研究Inmonkeyadrenalcells,orteronelinhibitstheACTHstimulatedproductionofDHEAandandrostenedionewithIC50of110nMand130nM,respectively.Moreover,OrteronelalsopotentlyinhibitsDHEAproductioninhumanadrenocorticaltumorlineH295RcellswithIC50of37nM[1].Invitro,orteronelshowsthepotentinhibitoryactivityagainstratandhumansteroid17,20-lyasewithIC50of54nMand38nM,respectively.WhileotherCYPisoformsincluding11-hydroxylaseandCYP3A4arenotsignificantlyaffectedbyOrteronel.InmicrosomesexpressinghumanCYPisoforms,Orteronelexhibitgreaterinhibitoryeffectson17,20-lyasewithIC50of19nMcomparedtotheotherCYPisoforms[2].體內(nèi)研究Orteronel(1mg/kg,p.o.)resultsinfavorablepharmacokineticparameterswithTmax,Cmax,t1/2andAUC0-24hoursof1.7hours,0.147μg/mL,3.8hoursand0.727μg/mL,respectively[1].Incynomolgusmonkeys,oraltreatmentofOrteronelatadoseof1mg/kgmarkedlyreducesserumtestosteroneanddehydroepiandrosterone(DHEA)levels[2].PROTOCOLKinaseAssay[2]Rat11-hydroxylaseactivityismeasuredaccordingtoamethoddescribedforside-chaincleavageactivitypreviouslywithsomemodifications.Thereactionmixturecontained200mMmannitol,4.5mMHEPES,2.3mMpotassiumphosphate(pH7.4),0.1mMEDTA·2K,0.03%BSA(crystallized),4.5mMNADPH,11mMcalciumchloride,4μgofmitochondriaprotein,10nM[1,2-3H]-hydroxy-11-deoxycorticosterone(11-deoxycortisol)(NEN,dissolvedin0.02%Tween-80),and1-1000nMtestcompoundsinatotalvolumeof150μL.Theconcentrationsofreagentsareexpressedasthefinalconcentrationinthereactionmixture.Thetestcompoundsareseriallydilutedwithdimethylformamide,and1.5μLisaddeddirectlytothereactionmixture.After30minincubationat37°Cthereactionisterminatedbyadditionof400μLofethylacetateand100μLofdistilledwater,thenvortexedfor30sandbrieflycentrifuged.ThreehundredμLsoftheorganicphaseistransferredtoanewtubeandevaporateduntildryusingnitrogengas.Thesteroidsaredissolvedwith30μLofethylacetateandthewholevolumeisappliedtosilicagelTLCplates.Thesubstrateandtheproducts(11-deoxycortisolandcortisol)areseparatedinthetoluene-acetone(7:2)solventsystem.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEAnimalAdultmalecynomolgusmonkeyshousedinatemperature-controlledroom(23±2°C)witha12:12hlight/darkAdministration[2]cycle(illuminationfrom7:00amto7:00pm)areusedforthesingledosingexperiments.Thetestcompounds(+)-Orteroneland(?)-Orteronelaresuspendedin0.5%methylcelluloseandadministeredorallyatadoseof1mg/kg.Bloodsamplesarecollectedjustbeforedosingand8h(inapreliminarystudy)or2,5and10hafterdosing.Serumisstoredat?30°Cuntilassayedbyradioimmunoassay.ConcentrationsoftestosteroneandDHEAaredeterminedusingaTestosteroneI-125kitandaDHEARIAkit,respectively.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?SciRep.2016Aug26;6:32198.?Prostate.2017Dec;77(16):1550-1562.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].YamaokaM,etal.Orteronel(TAK-700),anovelnon-steroidal17,20-lyaseinhibitor:effectsonsteroidsynthesisinhumanandmonkeyadrenalcellsandserumsteroidlevelsincynomolgusmonkeys.JSteroidBiochemMolBiol.2012Apr;129(3-5):115-28.[2].Kaku,Tomohiro.,etal.Discoveryoforteronel(TAK-700),anaphthylmethylimidazolederivative,asahighlyselective17,20-lyaseinhibitorwithpotentialutilityinthetreatmentofprostatecancer.Fr
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 口腔解剖生理學(xué)-第十一章(面頸顱部局部解剖)
- 食品安全案例-課件案例十六-豆?jié){煮制不充分引起的食物中毒
- 小額個(gè)人貸款協(xié)議書范本
- 技術(shù)合同寫作指南:技術(shù)開發(fā)合同的主要條款撰寫
- 家庭聚會(huì)花卉布置協(xié)議
- 土地租賃期滿拆除協(xié)議
- 材料采購合同寫作技巧
- 裝修合同的主要內(nèi)容有哪些
- 標(biāo)準(zhǔn)住宅出租合同樣本
- 倉庫租賃合同書范本
- 2024-2030年中國磚瓦行業(yè)發(fā)展分析及發(fā)展前景與投資研究報(bào)告
- 運(yùn)用PDCA循環(huán)提高全麻患者體溫檢測(cè)率
- 人教版五年級(jí)英語上冊(cè)知識(shí)歸納
- 2024年秋季新人教版八年級(jí)上冊(cè)物理課件 3.5跨學(xué)科實(shí)踐:探索廚房中的物態(tài)變化問題
- 外研版(2024)七年級(jí)上冊(cè)英語全冊(cè)教案教學(xué)設(shè)計(jì)
- 2024-2030年中國骨生長促進(jìn)劑行業(yè)市場發(fā)展趨勢(shì)與前景展望戰(zhàn)略分析報(bào)告
- 從業(yè)人員誠實(shí)守信和無犯罪記錄承諾書模板
- YYT 0916.1-2014 醫(yī)用液體和氣體用小孔徑連接件 第1部分:要求
- 2024電化學(xué)儲(chǔ)能電站巡視檢查項(xiàng)目表
- 綠化種植補(bǔ)種合同范本
- 生物質(zhì)黑顆粒技術(shù)介紹材料A
評(píng)論
0/150
提交評(píng)論